Study Findings from Sun Yat-sen University Cancer Center Update Knowledge in Cervical Cancer (Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial).
In: Women's Health Weekly, 2024-06-25, S. 1421-1421
serialPeriodical
Zugriff:
A study conducted at Sun Yat-sen University Cancer Center in Guangzhou, China, evaluated the efficacy and safety of Sintilimab, paclitaxel, and cisplatin as neoadjuvant therapy for locally advanced cervical cancer. The study included 47 patients with stage IB3 or IIA2 cervical cancer who received three cycles of neoadjuvant chemotherapy followed by radical surgery. The primary endpoint of the study was the pathological complete remission rate, which was found to be 32.6%. The study concluded that Sintilimab plus paclitaxel and cisplatin showed promising antitumor activity with manageable side effects in patients with locally advanced cervical cancer. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Study Findings from Sun Yat-sen University Cancer Center Update Knowledge in Cervical Cancer (Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial).
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-06-25, S. 1421-1421 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Schlagwort: |
|
Sonstiges: |
|